Fractional Exhaled Nitric Oxide and Exacerbations of COPD

Starting soon

Conditions studied: Chronic Obstructive Pulmonary Disease (COPD)

In brief

Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition with recurrent exacerbations despite guideline-based therapy. This prospective observational cohort study aims to evaluate whether baseline fractional exhaled nitric oxide (FeNO), a biomarker of type 2 airway inflammation, predicts future exacerbations and lung function decline in COPD patients initiated on triple inhaler therapy in routine clinical practice. The study will also explore the relationships between air pollution exposure, type 2 inflammatory biomarkers, and COPD outcomes.

Key facts

Study ID

NCT07396311

Run by

Chang Gung Memorial Hospital

People needed

120

Starts

2026-03-01

Expected to finish

2028-02-29

Last updated by the study team

2026-02-09

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged 40 years or older
• Diagnosis of chronic obstructive pulmonary disease (COPD) confirmed by post-bronchodilator spirometry (FEV₁/FVC < 0.70).
• History of cigarette smoking
• Receiving triple inhaler therapy (inhaled corticosteroid/long-acting beta-agonist/long-acting muscarinic antagonist) as part of routine clinical care, including:
• patients who have been previously escalated to triple inhaler therapy due to prior exacerbations and are already receiving triple therapy at the time of enrollment, and
• patients who are newly prescribed triple inhaler therapy at or immediately before enrollment because of a recent exacerbation.

Where it is running

• Chang Gung Medical Foundation — Taoyuan, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.